• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Operating Officer Cittadine Andrew

    3/7/25 9:09:50 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Cittadine Andrew

    (Last) (First) (Middle)
    1000 SKOKIE BLVD SUITE 350

    (Street)
    WILMETTE IL 60091

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Monopar Therapeutics [ MNPR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $31.7 03/04/2025 A 43,445 (1) 03/04/2035 Common Stock 43,445 $0 43,445 D
    Restricted Stock Units $0 03/04/2025 A 40,581 (2) (2) Common Stock 40,581 $0 51,655 D
    Explanation of Responses:
    1. Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter.
    2. RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.
    /s/ Quan Vu, Attorney-in-fact 03/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MNPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    9/9/2025$87.00Buy
    BTIG Research
    9/3/2025$77.00Outperform
    Oppenheimer
    9/3/2025$80.00Strong Buy
    Raymond James
    8/26/2025$70.00Buy
    H.C. Wainwright
    7/7/2025$74.00Overweight
    Cantor Fitzgerald
    6/23/2025$60.00Buy
    Chardan Capital Markets
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    More analyst ratings

    $MNPR
    SEC Filings

    View All

    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    9/15/25 7:00:11 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Monopar Therapeutics Inc.

    EFFECT - Monopar Therapeutics (0001645469) (Filer)

    9/10/25 12:15:22 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Monopar Therapeutics Inc.

    S-3 - Monopar Therapeutics (0001645469) (Filer)

    8/29/25 4:40:18 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tsuchimoto Kim R exercised 8,904 in-the-money shares at a strike of $0.01 and sold $356,171 worth of shares (8,904 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:06:13 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Starr Christopher M exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:03:50 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Robinson Chandler exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:02:07 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

    WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of

    9/14/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

    WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association (ANA) Annual Meeting, to be held September 13-16, 2025, in Baltimore, Maryland. The abstract, titled "Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline,"

    9/3/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

    WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On June 6, 2025, Alexion Pharmaceuticals officially transferred sponsorship of the investigational new drug ("IND") application for ALXN1840 to Monopar. The U.S. Food and Drug Administration ("FDA") acknowledged this change on July 29, 2025, confirming that the transfer was effective as of June 6, 2025. Monopar is now fu

    8/12/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    10/30/24 4:17:28 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/21/24 5:16:51 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/17/24 6:08:20 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    View All

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

    Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

    1/23/25 1:10:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

    WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini

    7/12/21 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

    WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization

    6/1/21 4:05:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    11/6/24 3:13:14 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    10/31/24 4:17:57 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Monopar Therapeutics with a new price target

    BTIG Research initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $87.00

    9/9/25 7:59:49 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Monopar Therapeutics with a new price target

    Oppenheimer initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $77.00

    9/3/25 8:38:53 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Monopar Therapeutics with a new price target

    Raymond James initiated coverage of Monopar Therapeutics with a rating of Strong Buy and set a new price target of $80.00

    9/3/25 8:38:32 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care